by Raynovich Rod | May 10, 2017 | 2024 Rayno Tools and Diagnostics Portfolio
Hologic, Inc. (HOLX) Beats: Revenues Increased 3.2% and GAAP diluted Earnings Increased 666.7% Compared to Prior Year Period (fiscal Q2) The base business grew 5.4% lead by molecular diagnostics, surgical and international franchises.Restructuring completed. The newly...
by Raynovich Rod | Jan 20, 2017 | Clinical Diagnostics and Tools
Outlook and Issues for Application of NGS for Clinical Diagnostics We heard a few presentations on NGS solutions and still think it is an important growth market for clinical diagnostics in oncology, rare diseases transplant medicine and NIPT. Gene sequencing (NGS)...
by Raynovich Rod | Jan 10, 2017 | Biopharmaceuticals, Clinical Diagnostics and Tools
Wet Stormy Weather in San Francisco-A New Indicator for a Good Year Ahead? About 8000+ investors, entrepreneurs and life science Company executives piled into the Westin St. Francis for the Annual J.P.Morgan Healthcare Conference and maybe 10k+ others at several other...
by Raynovich Rod | Dec 20, 2016 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Sector: What’s Going On With Dx and Tools Stocks? We dropped coverage of Life Science diagnostics and tools stocks in January 2016 just after the severe market correction began. Of course the downdraft opened up great values in several stocks.We...
by Raynovich Rod | Oct 21, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
CLIA Labs Offer Liquid Biopsy Tests for Cancer and Precision Medicine We attended presentations from two emerging companies developing molecular diagnostics platforms focused in cancer.Their mission is to develop cost-effective, non-invasive diagnostic assays and...
by Raynovich Rod | Oct 20, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
Microbiomes: A New Paradigm for Drug Discovery? Focus: Drugs From Gut Bacteria You may have read a few articles about the impact of the microbiomes and their impact on diets, digestion and nutrition but now there is the potential of discovering new therapies from...
by Raynovich Rod | Oct 11, 2016 | Clinical Diagnostics and Tools
Update-1 Biotechs Sinking Again …IBB down 2.48%, ILMN down another 2% Related sequencing stocks: FMI down 1.75%, PACB flat at $8.40 Illumina (ILMN) Shares Crash on Revenue Miss Illumina (ILMN) shares crashed 25% to $139, after a warning on third quarter sales ....
by Raynovich Rod | Sep 6, 2016 | Clinical Diagnostics and Tools
M&A Deal of the Day: Cepheid (CPHD) up 50% Over Friday Close on Cash Buyout We have been spending too much time on biopharma. It is time to dust off our Dx and Tools portfolio, which is on hold, and find some value stocks for Q4 moves. We did an update in Q4 of...
by Raynovich Rod | Aug 18, 2016 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
Illumina (ILMN) Up 3 % to $174 on Buyout Speculation in Gene Sequencing Illumina, Inc. (ILMN) was up as much as 12 points earlier today on a rumored buyout from Thermo Fisher Scientific Inc. (TMO). Thermo bought another major player in sequencing Life Techologies for...
by Raynovich Rod | Aug 10, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update August 15 : Biotech Leads But Healthcare Sector Lags IBB up 0.92% to $295, XBI up 1.33% to $63.35, XLV up 0.17% to $74.91 The tape was pretty decent despite a quiet day with ALXN up 1.97%, AMGN up 1.49% and CELG up 1.08%. Mid-caps also found bids: ALKS up...
